Home   |   US Site   |   Contact Us   |   Site Map
Press Release

bundestag healthcare committee

Back to News & Events

A Delegation of the Healthcare Committee of the German Parliament Visits TransMedics, Inc. in Review of Anticipated German Heart Transplant Initiative Using the OCS™

Andover, Massachusetts, USA - May 12, 2011

TransMedics, a global medical device company and the manufacturer of the Organ Care System (OCS™) technology, hosted a delegation of seven leading members of the Bundestag’s (Parliamentary) healthcare committee, representing all party-groups in Parliament, chaired by Dr. Carola Reimann, at its corporate headquarters in Andover, Massachusetts.

During their visit, world-renowned heart and lung transplant expert Prof. Dr. med Martin Strueber of Hannover Medical School, Hannover, Germany, updated the delegation on the current critical status of heart and lung transplantation in Germany and the potential for the OCS™ technology to effect dramatic improvements.

The delegation was very keen to understand the status of the negotiations with GKV SV relating to the much-anticipated start of the OCS™ Heart transplant clinical program in Germany. “OCS is a very important technology supporting heart and lung transplantation in a new and more efficient way,” said Dr. Carola Reimann, chairwoman of the Health Committee. "It reduces the risk of ischemia injury, extends the time of transport and expands the rate of utilization of donated organs.”

“We are honored by the visit and support from Dr. Reimann and members of Health Committee,” said Dr. Waleed Hassanein, President and CEO of TransMedics, Inc. “We are very committed to providing access to our life saving OCS technology to German patients. TransMedics has been working diligently over the past three years with the relevant stakeholders in the German healthcare system to develop this program to its current status. We are hopeful that we can overcome the last hurdle to start this world-class program in the next few weeks.”

Background on the German Heart Transplant Initiative with The OCS™ Technology:

In collaboration with the leading seven heart transplant centers in Germany, a world-class registry program was developed to evaluate the clinical impact of the use of OCS™ technology on improving post transplant outcomes and expanding the rate of utilization of donor hearts in Germany. This registry protocol has been recently approved by the Ständigen Kommission Organtransplantation der BÄK and relevant ethics committee boards. The OCS program is governed by the Deutsche Stiftung Organtransplantation (DSO) and supported by its stakeholders, GKV SV, DKG and BÄK. The clinical and Scientific oversight of this critical program is under the leadership of a clinical steering committee with representation from the following institutions:

  • Medizinischen Hochschule Hannover
  • Deutsches Herzzentrum Berlin
  • Albert-Ludwigs-Universität Freiburg
  • Universitäres Herzzentrum Hamburg
  • Herz- und Diabeteszentrum NRW in Bad Oeynhausen
  • Universitätsklinikum Heidelberg
  • Klinikum der Universität München - Grosshadern

What is the TransMedics® Organ Care System?

Since the advent of transplantation, the cornerstone of organ preservation has been cold ischemic storage (organs on ice). Although this method is intended to help reduce the extent of organ damage during transport, significant damage still occurs. The more time that passes, the more damage that occurs. Moreover, the cold storage technique does not enable any optimization or assessment capabilities, thus directly results in wasting a large percentage of available organs for transplantation. It is estimated that only 30-40% of donor hearts are utilized for transplantation globally based on the limitations of cold storage.

TransMedics has developed the world’s only medical device capable of overcoming the above limitations of cold storage for organ transplantation. The Organ Care System (OCS™) technology was designed to provide a comprehensive solution to all three key limitations of cold storage technique. The OCS™:

  • Limits ischemia injury by perfusing the organs with oxygenated blood;
  • Optimizes the condition of organs by replenishing oxygen, nutrients and hormones that are depleted;
  • Provides continuous monitoring and assessment capabilities for the organs until the point of transplantation

These unique capabilities of the OCS™ technology result in:

  • Improved patient survival
  • Reduction in post transplant complications
  • Increase in organ utilization of current donor organs
  • Improved cost-effectiveness of the transplant procedure

Media Contacts:

TransMedics, Inc.
Neal Beswick
VP Global Marketing

Tel: (978) 289-2615

Back to News & Events
©2017 TransMedics, Inc.   |   Privacy Policy   |   Legal Notice